



January 30, 2024

To
The Manager
Listing Compliance
**Bombay Stock Exchange
Limited** P.J.Towers, Dalal Street,
Mumbai-4400 001, Maharashtra,
India
SCRIP CODE: 543919

To
The Manager
Listing Compliance
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex, Bandra
East, Mumbai – 400051
NSE SYMBOL: MKPL

Sub: Outcome of Board Meeting held on January 30, 2024

In terms of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at their meeting held on Tuesday, January 30, 2024, *inter-alia*, considered and approved the following business items:

1. UN-AUDITED FINANCIAL RESULTS OF THE COMPANY

The Un-audited Financial Results of the Company for the quarter and nine months ended December 31, 2023, duly reviewed by the Audit committee, along with Limited Review Report for same. Copy of the same is enclosed herewith for your reference as **Annexure-I**.

2. BONUS ISSUE TO THE EXISTING SHAREHOLDERS OF THE COMPANY

The proposal of issuance of Bonus equity shares to the existing shareholders of the Company in the ratio of 2 : 1 i.e. 2 (Two) fully paid-up bonus equity shares of face value of Re. 1/- (Rupee One Only) each for every 1 (One) existing fully paid-up equity shares having a face value of Re. 1/- (Rupee One Only) each held by the eligible shareholders of the Company as on the record date, subject to the approval of shareholders and such other approvals as may be required.

Record date to determine the eligible shareholders shall be decided and will be intimated to the stock exchanges in due course.

*Disclosure with respect to the Bonus Issue under Regulation 30 of SEBI Listing Regulations read with SEBI circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 is enclosed as **Annexure II** to this letter.*

3. INCREASE IN AUTHORIZED SHARE CAPITAL OF THE COMPANY

The increase in Authorised Share Capital of the Company from Rs. 15,00,00,000 (Rupees Fifteen Crores Only) divided into 15,00,00,000 (Fifteen Crores Only) Equity Shares of Re. 1/- each to Rs. 40,00,00,000 (Rupees Forty Crores Only) divided into 40,00,00,000 (Forty Crores Only) Equity Shares of Re. 1/- each and consequent amendment in the Capital Clause (Clause V) of Memorandum of Association of the Company, subject to the approval of shareholders.

4. MEMBERS' APPROVAL THROUGH POSTAL BALLOT

To seek members' approval through the process of postal ballot for the above-said today's board decision and approved the draft notice of Postal Ballot, appointment of scrutinizer and other incidental activities.

M. K. Proteins Limited

Naraingarh Road, Village Garnala, Ambala City (Haryana), India - 134003
T : 0171-2679358 | W: www.mkproteins.in | E: compliancemkproteins@gmail.com
CIN : L15500HR2012PLC046239 | ISIN : INE964W01013



The notice of the same shall be sent separately to the Stock Exchange(s) and to the Members of the Company and will also be available on the Company's and stock exchange(s) websites, in due course.

The Board meeting commenced at 06:00 P.M. and concluded at 06:30 P.M.

You are requested to take the information on record and oblige.

Thanking you,
Yours Faithfully,

For M K Proteins Limited

Parmod Digitally signed by
Kumar Parmod Kumar
Date: 2024.01.30
18:38:43 +05'30'

Parmod Kumar
Managing Director
DIN: 00126965

M. K. Proteins Limited

Naraingarh Road, Village Garnala, Ambala City (Haryana), India - 134003
T : 0171-2679358 | W: www.mkproteins.in | E: compliancemkproteins@gmail.com
CIN : L15500HR2012PLC046239 | ISIN : INE964W01013



K R A & C O.

Chartered Accountants

☎ 011 - 47082855
Fax: 011 - 47082855

H -1/208, Garg Tower, Netaji Subhash Place, Pitampura, New Delhi -110034

Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results of the Company pursuant to the regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of M. K. Protiens Limited

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results ("the Statement") of **M. K. Protiens Limited** ('the Company') for the quarter ended December 31, 2023 ('the Statement'), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulation').
2. This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("IND AS 34") prescribed under section 133 of the Companies Act 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of Securities and Exchange Board of India (Listing and Disclosure Requirements) Regulations, 2015. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For KRA & Co.

Chartered Accountants

(Firm Registration No.020266N)



Rajat Goyal

Partner

Membership No.: 503150

UDIN: 24503150BKALNP5236

Place: New Delhi

Date: 30th January 2024

M. K. PROTEINS LIMITED

Regd. Office: Naraingarh Road, Village Gamala, Ambala City (Haryana), India - 134003
T: 0171-2679358 | W: www.mkproteins.in | E: compliancemkproteins@gmail.com
CIN: L15500HR2012PLC046239 | ISIN: INE964W01013

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER / NINE MONTH ENDED 31ST DECEMBER 2023

(Rs. In Lakh)

S. NO	PARTICULARS	QUARTER ENDED		NINE MONTH ENDED	YEAR ENDED
		31-12-2023 (UNAUDITED)	30-09-2023 (UNAUDITED)	31-12-2023 (UNAUDITED)	31-03-2023 (AUDITED)
1.	Revenue				
a)	Revenue from Operation (Net)	6886.26	1364.05	15869.82	31486.00
b)	Other Income	0.64	2.98	3.62	5.69
	Sub-Total "1"	6886.90	1367.03	15873.44	31491.69
2.	Expenditure				
a)	Cost of Material Consumed	5736.72	497.72	9427.33	25574.42
b)	Purchase of Stock-in-Trade	598.33	880.22	2935.66	4912.19
c)	Change in inventories of Finished Goods, Work-in-progress and Stock-in-Trade	(124.37)	(221.34)	1761.99	(1967.95)
d)	Employees Benefits Expenses	63.47	67.35	199.54	176.29
e)	Manufacturing, Operating and Other Expenses	256.46	76.25	725.94	1087.19
f)	Finance Costs	10.71	3.64	66.72	173.37
g)	Depreciation and Amortization Expenses	11.74	11.74	35.09	75.77
	Sub-Total "2"	6553.06	1315.58	15152.27	30031.28
3	Profit/(Loss) before Exceptional, Extraordinary items and Tax [1 – 2]	333.84	51.45	721.17	1460.41
4	Exceptional Items	0.00	0.00	0.00	0.00
5	Profit/(Loss) before Extraordinary items and Tax [3 – 4]	333.84	51.45	721.17	1460.41
6	Extraordinary Items	0.00	0.00	0.00	0.00
7	Profit/(Loss) before Tax [5 – 6]	333.84	51.45	721.17	1460.41
8	Tax Expenses				
a)	Provision for Current Tax	83.58	11.63	181.58	399.52
b)	Provision for Deferred Tax Liability/(Adjustment)	2.30	(1.38)	1.38	(3.71)
c)	Prior Year Taxes	0.00	0.00	0.00	0.00
	Sub-Total "8"	85.88	10.25	182.96	395.81
9	Profit/(Loss) for the Period from continuing operations [7 - 8]	247.96	41.20	538.21	1064.60
10	Profit/(Loss) for the period from Discontinuing operations before tax	0.00	0.00	0.00	0.00
11	Tax expenses of Discontinuing operations	0.00	0.00	0.00	0.00
12	Profit/(Loss) from Discontinuing operations (After Tax) [10 – 11]	0.00	0.00	0.00	0.00
13	Profit/(Loss) for the period [9 + 12]	247.96	41.20	538.21	1064.60
14	Other Comprehensive Income net of taxes				
a)	(i) Amount of items that will not be reclassified to profit and loss	0.00	0.00	0.00	0.00
	(ii) Income Tax relating to items that will not be reclassified to profit and loss	0.00	0.00	0.00	0.00
b)	(i) Amount of items that will be reclassified to profit and loss	0.00	0.00	0.00	0.00
	(ii) Income Tax relating to items that will be reclassified to profit and loss	0.00	0.00	0.00	0.00
	Sub- Total "14"	0.00	0.00	0.00	0.00
15	Total comprehensive Income for the Period [13 + 14]	247.96	41.20	538.21	1064.60
16	Earnings per share				
a)	Earnings per Equity Share for continuing operations				
	Basic earnings/(Loss) per share from continuing operations	0.20	0.33	0.43	8.51
	Diluted earning/(Loss) per share from continuing operations	0.20	0.33	0.43	8.51
b)	Earnings per Equity Share for discontinuing operations				
	Basic earning/(Loss) per share from discontinuing operations	0.00	0.00	0.00	0.00
	Diluted earning/(Loss) per share from discontinuing operations	0.00	0.00	0.00	0.00

Parmod Kumar
Digitally signed by
Parmod Kumar
Date: 2024.01.30
18:38:09 +05'30'

c)	Earnings per Equity Share				
	Basic earning/(Loss) per share from continuing and discontinuing operations	0.20	0.33	0.43	8.51
	Diluted earning/(Loss) per share from continuing and discontinuing operations	0.20	0.33	0.43	8.51
17	Details of Equity Share Capital				
	Paid-up Equity Share Capital	1251.24	1251.24	1251.24	1251.24
	Face value of Equity Share Capital	1	10	1	10
18	Other Equity [Reserves]	-	-	-	3775.94

Note:

1. The above mentioned audited results were reviewed by the Audit Committee and approved by the Board of Directors of the Company at its meeting held on 30th January, 24.
2. Previous year figures have been regrouped / rearranged, wherever necessary, to confirm with the current period classification.
3. The above results have been reviewed by the Statutory Auditor as required under regulation 33 of SEBI (Listing Obligations and disclosures Requirements) Regulations, 2015.
4. During the period, the shareholders of the Company have through Postal Ballot on 25th October, 2023 approved the sub-division of face value of the Equity Shares of the Company from Rs. 10/- (Rupees Ten only) to Rs. 1/- (Rupee One only). Accordingly, the holder(s) of the Equity Shares of the Company have received "10" Equity Shares of face value of Rs. 1/- each in lieu of "1" Equity Share of face value of Rs. 10/- each and accordingly the number of equity shares in the paid up equity capital of the Company has been changed from the 10th November, 2023 onwards.
5. The trading in the equity share of the Company has been migrated from SME Emerge platform to Main Board of the NSE w.e.f. 13th June 2023 and also listed on Bombay Stock Exchange (BSE) on 12th June 2023, therefore quarterly result are required to be presented from first Quarter of financial year 2023-24 i.e. 30th June 2023 onwards. Hence the corresponding figures of quarter ended on 31st December 2022 and nine month figures ended 31st December 2022 are not presented here.
6. The Company is engaged in single business activity (i.e. Manufacturing of Vegetable Refined oil) and there is no separate reportable segment.
7. The Company has adopted Indian Accounting Standard ("Ind As") with effect from 1st April 2023 and the financial results for the quarter ended 31st December, 2023 has been prepared as per the recognition and measurement principles of Ind As. The management has exercised necessary due diligence and ensured that the financial results provided true and fair view of its affairs in accordance with the companies (Indian Accounting Standards) Rule 2015. These results have been disclosed in the format specified in Schedule III of the Companies Act, 2013 as prescribed by the Circular on "Revised Format for financial Results and Implementation of Ind AS by listed Entities dated 5th July 2016 issued by SEBI.

For and on behalf of the board

Place: Ambala
Dated: 30-01-2024

Parmod Kumar Digitally signed
by Parmod Kumar
Date: 2024.01.30
18:37:21 +05'30'

(Parmod Kumar)
Managing Director
DIN: 00126965



M K PROTEINS

Annexure-II

The detailed disclosure as required under Regulation 30 of the SEBI (Listing Disclosure Obligations and Requirements) Regulations, 2015 read with SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 with respect to issuance of Bonus Equity Shares:

Sr No	Particulars	Disclosure
1	Types of Securities proposed to be issued (viz. equity shares, convertibles etc.)	Equity Shares
2	Type of issuance (further public offering, rights issue, depository receipts (ADR/GDR), qualified institutions placement, preferential allotment etc.)	Bonus Issue
3	Total number of securities proposed to be issued or the total amount for which the securities will be issued (approximately)	25,02,48,000 Equity Shares of face value of Re.1/- each fully paid-up.
4	Whether bonus is out of free reserves created out of profits or share premium account	Bonus shares will be issued out of Securities Premium account/retained earnings/ free reserves or any other permitted reserves/surplus of the Company of the Company available as at December 31, 2023.
5	Bonus ratio	2:1 i.e. 2 (Two) fully paid-up bonus equity shares of Re. 1/- (Rupee One Only) each for every 1 (One) existing fully paid-up equity shares having a face value of Re. 1/- (Rupee One Only) each held on record date.
6	Details of share capital - pre and post bonus issue	Pre-Bonus issue Paid up capital: Paid-up share capital Rs. 12,51,24,000/- divided into 12,51,24,000 equity shares of Re. 1/- each. Post-Bonus issue Paid up capital: Paid-up share capital of Rs. 37,53,72,000/- divided into 37,53,72,000 equity shares of Re. 1/- each.
7	Free reserves and/ or share premium required for implementing the bonus issue	Rs. 25,02,48,000/- is required for implementing the Bonus Issue
8	Free reserves and/ or share premium available for capitalization and the date as on which such balance is available	As on December 31, 2023 The balance of Rs. 3478.78 Lacs is available in free reserves account and Rs 835.37 Lacs is available in Securities Premium Account.
9	Whether the aforesaid figures are audited	Un-audited
10	Estimated date by which such bonus shares would be credited/dispatched	Within 2 months from the date of Board's approval

Parmod Kumar
Digitally signed by Parmod Kumar
Date: 2024.01.30 18:39:11 +05'30'

M. K. Proteins Limited

Naraingarh Road, Village Garnala, Ambala City (Haryana), India - 134003
T : 0171-2679358 | W: www.mkproteins.in | E: compliancemkproteins@gmail.com
CIN : L15500HR2012PLC046239 | ISIN : INE964W01013